Home :: Medication :: Ethyol

Latest Ethyol News

MedImmune Reports 2005 Financial Results - PR Newswire (press release)

- Annual Worldwide Sales of Synagis(R) Exceed $1 Billion for First Time - Major Milestones Achieved in 2005 * $1.2 billion in 2005 total revenues, increasing nine percent over 2004 * RSV franchise strengthened and expanded - Worldwide Sales of Synagis grew 13 percent to $1.1 billion in 2005 - U.S. co-promotion and international distribution agreements for Synagis restructured providing substantial strategic, operational and financial benefits - Completed enrollment in two late-stage studies with Numax(TM) - Converted to liquid formulation of Synagis in U.S. - Began clinical testing with combination vaccine against RSV and PIV-3 - In-licensed rights to anti-RSV small molecule compounds * Substantial progress achieved with influenza vaccine franchise - Pivotal Phase 3 trial results showed refrigerator-stable formulation of FluMist(R), CAIV-T, was 55 percent More effective than flu shot - sBLA for CAIV-T submitted to FDA for approval for use in healthy 5-49 year olds - State-of-the-art influenza vaccine Manufacturing facility approved by FDA - Patent estate expanded for using reverse genetics in influenza vaccine production - Entered into a research agreement with NIH to develop pandemic influenza vaccines * 11 new targets added to R&D portfolio * Three Investigational New Drug applications filed * HPV vaccine license - More available

Ethyol

No Ebay Marketplace Listings Found